Pregnan-3-ol-20-ones

Abstract

This invention provides a method of providing progestational therapy to a mammal in need thereof which comprises administering a progestationally effective amount of a pharmaceutically acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester to said mammal.

What is claimed is:  
     
         1 . A method of providing progestational therapy to a mammal in need thereof which comprises administering a progestationally effective amount of a pharmaceutically acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester to said mammal to said mammal.  
     
     
         2 . The method according to    claim 1   , wherein the pharmaceutically acceptable salt of the 3-sulfate ester is an alkaline metal salt, alkaline earth metal salt, ammonium salt, alkylammonium salt containing 1-6 carbon atoms, or dialkylammonium salt containing 1-6 carbon atoms in each alkyl group, or trialkylammonium salt containing 1-6 carbon atoms in each alkyl group.  
     
     
         3 . A method of treating or inhibiting cancers, central nervous system disorders, dementias, or Alzheimer's disease in a mammal in need thereof, which comprises administering a progestationally effective amount of a pharmaceutically acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester to said mammal to said mammal.  
     
     
         4 . The method according to    claim 3   , wherein the pharmaceutically acceptable salt of the 3-sulfate ester is an alkali metal salt, alkaline earth metal salt, ammonium salt, alkylammonium salt containing 1-6 carbon atoms, or dialkylammonium salt containing 1-6 carbon atoms in each alkyl group, or trialkylammonium salt containing 1-6 carbon atoms in each alkyl group.  
     
     
         5 . A method of providing progestational therapy to a mammal in need thereof which comprises administering a progestationally effective amount of a composition of matter consisting essentially of a pharmaceutically acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester to said mammal to said mammal.  
     
     
         6 . The method according to    claim 5   , wherein the pharmaceutically acceptable salt of the 3-sulfate ester is an alkali metal salt, alkaline earth metal salt, ammonium salt, alkylammonium salt containing 1-6 carbon atoms, or dialkylammonium salt containing 1-6 carbon atoms in each alkyl group, or trialkylammonium salt containing 1-6 carbon atoms in each alkyl group.  
     
     
         7 . A method of treating or inhibiting cancers, central nervous system disorders, dementias, or Alzheimer's disease in a mammal in need thereof, which comprises administering a progestationally effective amount of a composition of matter consisting essentially of a pharmaceutically acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester to said mammal to said mammal.  
     
     
         8 . The method according to    claim 7   , wherein the pharmaceutically acceptable salt of the 3-sulfate ester is an alkali metal salt, alkaline earth metal salt, ammonium salt, alkylammonium salt containing 1-6 carbon atoms, or dialkylammonium salt containing 1-6 carbon atoms in each alkyl group, or trialkylammonium salt containing 1-6 carbon atoms in each alkyl group.  
     
     
         9 . A method of providing cognition enhancement to a mammal in need thereof which comprises administering a cognition enhancement effective amount of a pharmaceutically acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester to said mammal to said mammal.  
     
     
         10 . The method according to    claim 9   , wherein the pharmaceutically acceptable salt of the 3-sulfate ester is an alkli metal salt, alkaline earth metal salt, ammonium salt, alkylammonium salt containing 1-6 carbon atoms, or dialoylammonium salt containing 1-6 carbon atoms in each alkyl group, or trialkylammonium salt containing 1-6 carbon atoms in each alkyl group.